Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Bemarituzumab Plus mFOLFOX6 in FGFR2-Selected Advanced Gastric and Gastroesophageal Cancer
2017-003507-22Phase 3Completed
- Sponsor
- Five Prime Therapeutics, Inc.
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric cancer (GC) and esophagogastric junction cancer comparing Bemarituzumab + mFOLFOX6 with Placebo + mFOLFOX6 (2 arms). Primary endpoint: Overall survival. Started Jul 2018; status: completed.
02
Drugs
bemarituzumab
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on 2017-003507-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003507-22.